Price T Rowe Associates Inc Immuneering Corp Call Options Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMRX
# of Institutions
37Shares Held
4.78MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$3.01 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0808KShares$2.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$1.52 Million0.0% of portfolio
-
Morgan Stanley New York, NY467KShares$1.33 Million0.0% of portfolio
-
Southport Management, L.L.C. Wilson, WY245KShares$698,2501.61% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $75.2M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...